S. Ferretti

发表

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Joshua M. Korn, Derek Y. Chiang, Tara L. Naylor, 2015, Nature Medicine.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Steven B. Neuhauser, Yvonne A. Evrard, Matthew H. Brush, 2017, Cancer research.

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014, Molecular Cancer Therapeutics.

Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models

A. Prahallad, A. Kauffmann, H. Bitter, 2020, Computational and structural biotechnology journal.

Effect of adenosine A2A receptor activation in murine models of respiratory disorders.

Christopher S. Stevenson, C. Stevenson, S. Ferretti, 2006, American journal of physiology. Lung cellular and molecular physiology.

IL-17, Produced by Lymphocytes and Neutrophils, Is Necessary for Lipopolysaccharide-Induced Airway Neutrophilia: IL-15 as a Possible Trigger

S. Ferretti, Carol E. Jones, A. Trifilieff, 2003, The Journal of Immunology.

Comparison of [18F]-Tracers in Various Experimental Tumor Models by PET Imaging and Identification of an Early Response Biomarker for the Novel Microtubule Stabilizer Patupilone

S. Ametamey, S. Ferretti, M. Honer, 2009, Molecular Imaging and Biology.

Differential DNA synthesis in response to activation of protease-activated receptors on cultured guinea-pig tracheal smooth muscle cells

M. Ferretti, S. Ferretti, R. Corteling, 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

Therapeutic assessment of targeting ASNS combined with L-Asparaginase treatment in solid tumors and investigation of resistance mechanisms

G. G. Galli, D. Ruddy, S. Ferretti, 2020, bioRxiv.

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

J. Esteve, Bernard Pereira, S. Ferretti, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

Joerg Kallen, Pascal Furet, Keiichi Masuya, 2015, Journal of medicinal chemistry.

Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics.

S. Ferretti, P. Allegrini, P. McSheehy, 2009, Neoplasia.

Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

G. Demetri, R. Dummer, S. Ferretti, 2021, British Journal of Cancer.

CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo

S. Ferretti, R. Hillenbrand, E. Ferrero, 2021, Oncogenesis.

PAX8 and MECOM are interaction partners driving ovarian cancer

G. G. Galli, D. Erdmann, D. Schübeler, 2021, Nature Communications.

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/− mouse model

Eric Y. Durand, J. Lehár, W. Sellers, 2017, Proceedings of the National Academy of Sciences.

p53 dynamics vary between tissues and are linked with radiation sensitivity

Miles A. Miller, R. Weissleder, Y. Iwamoto, 2021, Nature Communications.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Eric Y. Durand, W. Sellers, Philipp Holzer, 2018, Cancer research.

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Hans Bitter, Joerg Kallen, Pascal Furet, 2015, eLife.

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.

Joel Greshock, Levi A Garraway, Fred Harbinski, 2016, Cancer research.

Small Molecule Therapeutics Characterization of the Novel and Speci fi c PI 3 K a Inhibitor NVP-BYL 719 and Development of the Patient Strati fi cation Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014 .

Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response

Jingwei Cheng, J. Decaprio, S. Ferretti, 2018, Proceedings of the National Academy of Sciences.

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

M. Rausch, M. Rudin, D. Baumann, 2005, NMR in biomedicine.

Patupilone Induced Vascular Disruption in Orthotopic Rodent Tumor Models Detected by Magnetic Resonance Imaging and Interstitial Fluid Pressure

Michael Stumm, C. Schnell, J. Wood, 2005, Clinical Cancer Research.

Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability

Didier Laurent, Michael Stumm, Claudia Weidensteiner, 2009, Clinical Cancer Research.

Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201

S. Ferretti, N. Guerreiro, C. Meille, 2021, The AAPS Journal.

Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma

K. Altmann, S. Ferretti, E. Buchdunger, 2005, Cancer Chemotherapy and Pharmacology.

M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth

W. Sellers, S. Ferretti, F. Hofmann, 2012, Proceedings of the National Academy of Sciences.

Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma

J. Blay, A. Italiano, S. Ferretti, 2018, Clinical Trials.

InducedVascular Disruption in Orthotopic Rodent TumorModels Detected byMagnetic Resonance Imaging and Interstitial Fluid Pressure

C. Schnell, S. Ferretti, T. O'reilly, 2005 .

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

Philipp Holzer, P. Furet, S. Ferretti, 2018, Bioorganic & medicinal chemistry letters.

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

W. Sellers, Philipp Holzer, P. Furet, 2015, eLife.

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results From a Proof-of-Concept, Phase Ib Study.

J. Blay, A. Italiano, S. Ferretti, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells – a preclinical MR study in mice

S. Ferretti, Vincent Romanet, P. Allegrini, 2014, BMC Cancer.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Eric Y. Durand, W. Sellers, Philipp Holzer, 2018, Cancer research.

Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability

S. Ferretti, P. Allegrini, C. Weidensteiner, 2009, Clinical Cancer Research.

Minimally invasive biomarkers for therapy monitoring.

H. Lane, C. Schnell, J. Wood, 2007, Ernst Schering Foundation symposium proceedings.

Quantified Tumor T1 Is a Generic Early-response Imaging Biomarker for Chemotherapy Reflecting Cell Viability Clinical Cancer Research

S. Ferretti, S. Ruetz, M. Stumm, 2022 .